Product Description
Prabotulinumtoxina is being developed by AEON Biopharma for the treatment of glabellar frown lines. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT04715048?term=Prabotulinumtoxina&draw=2&rank=6)
Mechanisms of Action: AChR Inhibitor
Novel Mechanism: No
Modality: Unknown
Route of Administration: Injection
FDA Designation: *
Approval Status: Approved
Approved Countries: Australia | United States
Approved Indications: None
Known Adverse Events: None
Company: AEON Biopharma
Company Location:
Company CEO:
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Canada, United States
Active Clinical Trial Count: 6
Recent & Upcoming Milestones
- Clinical Outcomes Reported - AEON Biopharma presented P2 Migraine Disorders results on 2024-05-03 for Prabotulinumtoxina
- Clinical Outcomes Reported - AEON Biopharma presented P2 Dystonia results on 2024-01-18 for Prabotulinumtoxina
Highest Development Phases
Phase 2: Dystonia|Dystonic Disorders|Glabellar Reflex|Migraine Disorders|Torticollis
Phase 1: Pregnancy Outcomes
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06604832 |
KDEJ24 | P1 |
Completed |
Glabellar Reflex |
2025-08-29 |
12% |
2025-10-23 |
Primary Endpoints |
NCT05807412 |
Pra vs Ona Spread 2023 | P1 |
Completed |
Pregnancy Outcomes |
2024-02-26 |
4% |
2024-03-14 |
Primary Completion Date|Primary Endpoints |
NCT04845178 |
ABP-20001 | P2 |
Completed |
Migraine Disorders |
2024-06-19 |
2% |
2024-09-20 |
|
NCT04871451 |
ABP-19002 | P2 |
Completed |
Torticollis|Dystonic Disorders|Dystonia |
2023-07-24 |
11% |
2024-08-23 |
Patient Enrollment|Primary Endpoints|Treatments |
NCT05129319 |
CTBH-03-2021 | P1 |
Completed |
Glabellar Reflex |
2023-06-15 |
12% |
2024-02-07 |
Primary Endpoints |
NCT05320393 |
EVOLUS-CLIN201 | P2 |
Completed |
Glabellar Reflex |
2023-05-22 |
2% |
2024-09-05 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
11/20/2025 |
News Article |
AEON Biopharma Announces First Closing of PIPE Investment and Provides Update on FDA Type 2a Meeting Scheduling |
|
11/14/2025 |
News Article |
Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
|
11/13/2025 |
News Article |
AEON Biopharma Announces Fundraise Totaling Up to ~$22 Million through Private Placement and Proposed Exchange of Daewoong Convertible Notes |
|
11/05/2025 |
News Article |
Evolus Reports Third Quarter 2025 Financial Results |